All In Biotech

Drug Trial Radar · NCT05961956

Study With NVDX3 for Treatment of Low Grade Degenerative Lumbar Spondylolisthesis

A Proof-of-concept Study With NVDX3, an Osteogenic Implant of Human Allogenic Origin, in the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis by Interbody Spine Fusion in Adults.

Last checked: Nov 19, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

5

Actual

Start

Oct 12, 2023

Primary completion

Apr 18, 2026

Study completion Apr 18, 2026

Sponsor

Lead sponsor
Novadip BiosciencesIndustry
Sponsor type
Industry
First posted
Jul 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, single arm, single-center clinical study to test NVDX3 in patients suffering from low grade one level degenerative lumbar (L1 - S1) spondylolisthesis. NVDX3 will be implanted during a single surgical intervention.

Conditions

  • Degenerative Lumbar Spondylolisthesis

Interventions

  • NVDX3Drug

    NVDX3 is implanted during a single surgical intervention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety EndpointTime frame: Up to 24 months post implant surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier de Luxembourg

    Luxembourg, Luxembourg

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.